Clinical Trial Update: Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of pevonedistat in combination with azacitidine (or decitabine) and venetoclax for acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dacogen (decitabine)
• Pevonedistat (pevonedistat)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Myelogenous Leukemia | Phase 1 | Status: TERMINATED